drugset / Trial / NCT05098327
Pioglitazone and Insulin Resistance in ADT
Phase 3
Withdrawn
State University of New York at Buffalo
National Center for Advancing Translational Sciences (NCATS) · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is being done to establish the mechanisms underlying insulin resistance (reduced insulin action that can lead to high blood sugar and maybe diabetes) in patients undergoing androgen deprivation therapy (ADT) for prostate carcinoma as well as to investigate the role of pioglitazone therapy in reduction/ reversal of that insulin resistance
Timeline
- Start
- 2021-08-01
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pioglitazone | Small molecule | 30 mg | — |